Basimglurant in Children, Adolescents, and Young Adults With TSC
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive Therapy in Children, Adolescents, and Young Adults With Uncontrolled Seizures Associated With Tuberous Sclerosis Complex A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-control ...
Tuberous Sclerosis Complex
Drug: Basimglurant with crossover to Placebo;Drug: Placebo with crossover to Basimglurant
Noema Pharma AG
NULL
Recruiting
5 Years
30 Years
All
54
Phase 2
United States;Australia;India;Israel;Italy;Poland;Spain;Turkey;United Kingdom